Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) shares shot up 15.1% on Friday . The stock traded as high as $1.52 and last traded at $1.45. 2,978,200 shares changed hands during mid-day trading, an increase of 571% from the average session volume of 443,950 shares. The stock had previously closed at $1.26.

Several research firms have weighed in on OHRP. ValuEngine upgraded Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Roth Capital began coverage on Ohr Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research downgraded Ohr Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, HC Wainwright set a $10.00 price target on Ohr Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 16th.

Several hedge funds and other institutional investors have recently bought and sold shares of OHRP. Cannell Peter B & Co. Inc. bought a new position in shares of Ohr Pharmaceuticals during the 2nd quarter valued at approximately $187,000. Renaissance Technologies LLC boosted its position in shares of Ohr Pharmaceuticals by 242.3% during the 1st quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock valued at $191,000 after acquiring an additional 162,600 shares during the last quarter. Wedbush Securities Inc. bought a new position in shares of Ohr Pharmaceuticals during the 3rd quarter valued at approximately $311,000. Garrison Bradford & Associates Inc. boosted its position in shares of Ohr Pharmaceuticals by 482.4% during the 3rd quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 412,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Ohr Pharmaceuticals by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after acquiring an additional 5,481 shares during the last quarter. Hedge funds and other institutional investors own 8.40% of the company’s stock.

WARNING: “Ohr Pharmaceuticals (OHRP) Shares Up 15.1%” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/08/ohr-pharmaceuticals-ohrp-shares-up-15-1.html.

Ohr Pharmaceuticals Company Profile

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Receive News & Stock Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.